{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:47:35Z","timestamp":1790606855654,"version":"4.1.0"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"\n Objective:<\/jats:title>\n The objective of this review was to estimate the population-based incidence and determine the types of severe infection and deaths experienced by patients with rheumatoid arthritis taking biologic agents.<\/jats:p>\n <\/jats:sec>\n \n Introduction:<\/jats:title>\n Since the late 1990s, various biologic and synthetic drugs have been developed to treat rheumatoid arthritis. In recent years, the incidence of severe infection in patients with rheumatoid arthritis in Western nations has been determined by observational studies; however, no systematic review has been conducted on this topic.<\/jats:p>\n <\/jats:sec>\n \n Inclusion criteria:<\/jats:title>\n The following inclusion criteria were considered: i) observational studies on patients with rheumatoid arthritis treated with biologic agents; ii) studies reporting the number of severe infections requiring hospitalization for treatment; iii) studies reporting person-years of observation data; and iv) studies based on rheumatoid arthritis registries, medical records from rheumatology centers, or insurance claim databases.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n PubMed, CINAHL, Embase, and Web of Science were searched to identify published studies. The reference lists of all studies selected for critical appraisal were screened for additional studies. Unpublished studies were searched on MedNar and OpenGrey databases. All the searches were updated on December 6, 2021. After removing the duplicates, 2 independent reviewers screened titles and abstracts against the inclusion criteria and then assessed full texts against the criteria. Two reviewers independently appraised the study and outcome levels for methodological quality using the critical appraisal instrument for cohort studies from JBI. Two reviewers extracted the relevant information related to severe infection and drugs.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Fifty-two studies from 21 countries reported severe infection rates associated with using 8 biologic agents, plus nonbiologic disease-modifying antirheumatic drugs. In total, 18,428 infections with 395,065 person-years of biologic drug exposure were included in the analysis. Thirty-five studies included infections in outpatients receiving intravenous antibiotic therapy. Fifteen studies reported the first episode of infection, and the remaining studies did not specify either the first or all of the episodes of infection. Inclusion of viral infection and\/or opportunistic infection varied among studies. Fifteen studies reported the site of infection; respiratory, skin\/soft tissue, urinary tract, and sepsis\/bacteremia were commonly reported. Ten studies reported the case fatality rates, ranging from 2.5% to 22.2%. Meta-analysis was conducted for 8 biologic agents and conventional disease-modifying antirheumatic drugs. The infection rate varied from 0.9 to 18.1\/100 person-years. The meta-analysis revealed an infection rate of 5.0\/100 person-years (95% CI 3.8\u20136.7) among patients receiving tumor necrosis factor inhibitors (heterogeneity 98.2%). The meta-analysis for the other 3 biologic agents revealed a point estimate of 5.5 to 8.7\/100 person-years with high heterogeneity. Sensitivity analysis indicated that registry-based studies were less likely to have very low or very high infection rates compared with other data sources. The definition of infection, the patient composition of the cohorts, and the type of databases appeared to be the primary sources of clinical and methodological heterogeneity.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Due to high statistical heterogeneity, the meta-analysis was not suited to estimating a summary measure of the infection rate. Developing standardized data collection is necessary to compare infection rates across studies.<\/jats:p>\n <\/jats:sec>\n \n Systematic review registration number:<\/jats:title>\n PROSPERO CRD42020175137<\/jats:p>\n <\/jats:sec>\n \n Supplemental Digital Content:<\/jats:title>\n A Japanese-language version of the abstract of this review is available as Supplemental Digital Content [http:\/\/links.lww.com\/SRX\/A8].<\/jats:p>\n <\/jats:sec>","DOI":"10.11124\/jbies-22-00048","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T13:06:10Z","timestamp":1673442370000},"page":"835-885","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Incidence of severe infection in patients with rheumatoid arthritis taking biologic agents: a systematic review"],"prefix":"10.11124","volume":"21","author":[{"given":"Kiyoko","family":"Makimoto","sequence":"first","affiliation":[{"name":"Osaka University, Suita, Osaka, Japan"},{"name":"The Japan Centre for Evidence Based Practice: A JBI Centre of Excellence, Osaka University, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Konno","sequence":"additional","affiliation":[{"name":"Hyogo Medical University, Hypgo, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Hyogo Medical University, Hypgo, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatsumi","family":"Kanzaki","sequence":"additional","affiliation":[{"name":"Hyogo Medical University, Hypgo, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Suto","sequence":"additional","affiliation":[{"name":"Nara Medical University, Kashihara, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,5]]},"reference":[{"issue":"2","key":"R1-20250613","first-page":"1011","article-title":"Rheumatoid arthritis treatments: a historical perspective","volume":"1","author":"Aggarwal","year":"2016","journal-title":"JSM Arthritis"},{"issue":"4","key":"R2-20250613","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/art.23538","article-title":"Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US","volume":"59","author":"Allaire","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"19","key":"R3-20250613","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"R6-20250613","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/BOR.0000000000000598","article-title":"Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?","volume":"31","author":"Jani","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"R7-20250613","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.rbr.2016.07.008","article-title":"Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies","volume":"56","author":"Cabral","year":"2016","journal-title":"Rev Bras Reumatol"},{"issue":"9","key":"R8-20250613","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"R9-20250613","first-page":"232","article-title":"Rheumatoid arthritis classification criteria \u2013 it\u2019s finally time to move on!","volume":"68","author":"Sokolove","year":"2010","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"7","key":"R12-20250613","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"3","key":"R13-20250613","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Based Healthc"},{"issue":"Pt A","key":"R14-20250613","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cct.2015.05.009","article-title":"Advances in the meta-analysis of heterogeneous clinical trials I: the inverse variance heterogeneity model","volume":"45","author":"Doi","year":"2015","journal-title":"Contemp Clin Trials"},{"issue":"9","key":"R15-20250613","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/acr.22602","article-title":"Consistency and utility of data items across European rheumatoid arthritis clinical cohorts and registers","volume":"67","author":"Rander","year":"2015","journal-title":"Arthritis Care Res"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"Aaltonen","year":"2015","journal-title":"J Rheumatol"},{"issue":"10","key":"R17-20250613","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/ard.2006.067660","article-title":"All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists","volume":"66","author":"Carmona","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"R19-20250613","first-page":"60","article-title":"Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECORD linkage on rheumatic disease study of the Italian Society for Rheumatology","volume":"37","author":"Carrara","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"R20-20250613","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/RHU.0000000000000935","article-title":"Incidence of infectious adverse events in patients with rheumatoid arthritis and spondyloarthritis on biologic drugs-data from the Brazilian Registry for Biologics Monitoring","volume":"26","author":"Cecconi","year":"2020","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"R21-20250613","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/acr.23824","article-title":"Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study","volume":"72","author":"Chen","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"Suppl 3","key":"R22-20250613","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1756-185X.12539","article-title":"Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan","volume":"17","author":"Chiu","year":"2014","journal-title":"Int J Rheumatic Dis"},{"issue":"4","key":"R23-20250613","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheumat"},{"issue":"2","key":"R24-20250613","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/acr.21713","article-title":"Use of a disease risk score to compare serious infections associated with anti-TNF therapy among high versus lower risk rheumatoid arthritis patients","volume":"65","author":"Curtis","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"R25-20250613","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheumat"},{"issue":"Suppl 10","key":"R26-20250613","first-page":"1010","article-title":"Infection and malignancy outcomes in patients with ra treated with abatacept: results from a multinational surveillance study","volume":"72","author":"Dominique","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"R27-20250613","first-page":"653","article-title":"Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying antirheumatic drugs","volume":"32","author":"Emery","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"R28-20250613","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.autrev.2008.11.002","article-title":"Serious infections during anti-TNF-alpha treatment in rheumatoid arthritis patients","volume":"8","author":"Favalli","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"9","key":"R29-20250613","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"R30-20250613","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/annrheumdis-2018-214326","article-title":"Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden","volume":"78","author":"Gron","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"R31-20250613","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/art.20228","article-title":"The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis","volume":"51","author":"Hansen","year":"2004","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"R32-20250613","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-017-1496-5","article-title":"One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national US rheumatoid arthritis registry","volume":"20","author":"Harrold","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"R33-20250613","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3899\/jrheum.190260","article-title":"Long-term, real-world safety of adalimumab in rheumatoid arthritis: analysis of a prospective US-based registry","volume":"47","author":"Harrold","year":"2020","journal-title":"J Rheumatol"},{"issue":"3","key":"R34-20250613","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/rheumatology\/kex446","article-title":"Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection","volume":"57","author":"Henry","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R35-20250613","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00296-006-0165-9","article-title":"Serious infections under treatment with TNF-antagonists compared to traditional DMARDs in patients with rheumatoid","volume":"27","author":"Inanc","year":"2006","journal-title":"Rheumatol Int"},{"issue":"4","key":"R36-20250613","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jbspin.2011.12.004","article-title":"Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections","volume":"79","author":"Isvy","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"Suppl 9","key":"R37-20250613","first-page":"1073","article-title":"The association of biologic drug-levels with infection risk: results from the British society for rheumatology biologics register for rheumatoid arthritis","volume":"70","author":"Jani","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"R38-20250613","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.semarthrit.2021.07.004","article-title":"The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea","volume":"51","author":"Jeon","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"R39-20250613","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semarthrit.2012.12.024","article-title":"Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis","volume":"43","author":"Johnston","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"R40-20250613","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3899\/jrheum.101009","article-title":"Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety","volume":"38","author":"Komano","year":"2011","journal-title":"J Rheumatol"},{"issue":"5","key":"R41-20250613","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"R42-20250613","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/rheumatology\/kev437","article-title":"Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology\u2019s ORA registry","volume":"55","author":"Lahaye","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"R43-20250613","first-page":"216","article-title":"Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study","volume":"33","author":"Lampropoulos","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"R44-20250613","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MD.0b013e318211106a","article-title":"TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis","volume":"90","author":"Lane","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"R45-20250613","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/rheumatology\/ker223","article-title":"Risk of infections in rheumatoid arthritis patients treated with tocilizumab","volume":"51","author":"Lang","year":"2012","journal-title":"Rheumatol (Oxford)"},{"issue":"11","key":"R46-20250613","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R47-20250613","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-018-1539-6","article-title":"Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study","volume":"20","author":"Machado","year":"2018","journal-title":"Arthritis Res Therap"},{"issue":"6","key":"R48-20250613","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.semarthrit.2019.01.009","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of serious infection: a population-based cohort study","volume":"48","author":"Montastruc","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"R49-20250613","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/rheumatology\/kex238","article-title":"Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE","volume":"56","author":"Morel","year":"2017","journal-title":"Rheumatol (Oxford)"},{"issue":"6","key":"R50-20250613","doi-asserted-by":"crossref","first-page":"e0179179","DOI":"10.1371\/journal.pone.0179179","article-title":"Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: a multicenter retrospective cohort study in Japan","volume":"12","author":"Mori","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"R51-20250613","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/ard.2004.028597","article-title":"Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice","volume":"64","author":"Neven","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"R52-20250613","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.semarthrit.2012.04.001","article-title":"Risk of significant infection in rheumatoid arthritis patients switching anti-tumor necrosis factor-alpha drugs","volume":"42","author":"Nguyen-Khoa","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"R53-20250613","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/acr2.11064","article-title":"Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease-modifying antirheumatic drugs","volume":"1","author":"Ozen","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"R54-20250613","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"R55-20250613","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s10067-019-04516-2","article-title":"Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR","volume":"38","author":"Ranza","year":"2019","journal-title":"Clinical Rheumatol"},{"issue":"6","key":"R56-20250613","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/annrheumdis-2017-212825","article-title":"Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Rutherford","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"R57-20250613","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/acr.21666","article-title":"Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis","volume":"64","author":"Sakai","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"R58-20250613","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00296-014-3045-8","article-title":"The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database","volume":"34","author":"Sakai","year":"2014","journal-title":"Rheumatol Int"},{"issue":"6","key":"R59-20250613","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/annrheumdis-2015-207362","article-title":"Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry","volume":"75","author":"Salmon","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"R60-20250613","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00296-017-3679-4","article-title":"Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis","volume":"37","author":"Schenfeld","year":"2017","journal-title":"Rheumatol Int"},{"issue":"6","key":"R61-20250613","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","article-title":"Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis","volume":"56","author":"Schneeweiss","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"R62-20250613","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/imj.14109","article-title":"Ten-year retrospective review of the incidence of serious infections in patients on biologic disease modifying agents for rheumatoid arthritis in three tertiary hospitals in Western Australia","volume":"49","author":"Sharma","year":"2019","journal-title":"Intern Med J"},{"issue":"9","key":"R63-20250613","first-page":"1533","article-title":"Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid","volume":"57","author":"Silva-Fernandez","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R64-20250613","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","article-title":"Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study","volume":"21","author":"Simon","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"R65-20250613","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s10067-020-05476-8","article-title":"Risk of serious infection, malignancy, or death in Japanese rheumatoid arthritis patients treated with a combination of abatacept and tacrolimus: a retrospective cohort study","volume":"40","author":"Tokunaga","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"6","key":"R66-20250613","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"72","author":"van Dartel","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"R67-20250613","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/art.39399","article-title":"Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"R68-20250613","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"1","key":"R70-20250613","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13075-017-1457-z","article-title":"Chinese registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis","volume":"19","author":"Jin","year":"2017","journal-title":"Arthritis Res Therapy"},{"issue":"4","key":"R71-20250613","doi-asserted-by":"crossref","first-page":"SR1","DOI":"10.12659\/MSM.881697","article-title":"Access to biologic treatment for rheumatoid arthritis in Central and Eastern European countries","volume":"17","author":"Orlewska","year":"2011","journal-title":"Med Sci Monit"},{"issue":"3","key":"R72-20250613","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41584-019-0170-5","article-title":"Treat-to-target in rheumatoid arthritis - are we there yet?","volume":"15","author":"van Vollenhoven","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"R73-20250613","doi-asserted-by":"crossref","first-page":"e000040","DOI":"10.1136\/rmdopen-2014-000040","article-title":"The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries","volume":"1","author":"Finckh","year":"2015","journal-title":"RMD Open"},{"key":"R74-20250613","first-page":"764518","article-title":"Long-term drug survival of TNF inhibitor therapy in RA patients: a systematic review of European National Drug Registers","author":"Arora","year":"2013","journal-title":"Int J Rheumatology"},{"key":"R75-20250613","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology"},{"issue":"8","key":"R76-20250613","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.clinthera.2017.06.009","article-title":"Real-world effectiveness of biologic disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis after etanercept discontinuation in the United Kingdom, France, and Germany","volume":"39","author":"Li","year":"2017","journal-title":"Clin Therapeut"},{"key":"R77-20250613","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40744-017-0078-y","article-title":"Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the Corrona RA Registry","volume":"4","author":"Strand","year":"2017","journal-title":"Rheumatol Ther"},{"key":"R78-20250613","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fphar.2019.00279","article-title":"Biologic therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities?","volume":"10","author":"Baumgart","year":"2019","journal-title":"Front Pharmacol"},{"issue":"Suppl 1","key":"R79-20250613","doi-asserted-by":"crossref","first-page":"129","DOI":"10.31138\/mjr.31.1.129","article-title":"Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies","volume":"31","author":"Thomas","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"R80-20250613","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DHPS.S28801","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","author":"Ali","year":"2013","journal-title":"Drug Healthc Patient Saf"},{"key":"R81-20250613","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1177\/1535370220939862","article-title":"Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors","volume":"245","author":"Li","year":"2020","journal-title":"Experiment Biol Med"}],"container-title":["JBI Evidence Synthesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.11124\/JBIES-22-00048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:33:35Z","timestamp":1786451615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.11124\/JBIES-22-00048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":78,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.11124\/jbies-22-00048","relation":{},"ISSN":["2689-8381"],"issn-type":[{"value":"2689-8381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]}}}